HUP9901790A2 - Kationos viroszómák mint genetikai anyag bevitelére alkalmas rendszerek - Google Patents

Kationos viroszómák mint genetikai anyag bevitelére alkalmas rendszerek

Info

Publication number
HUP9901790A2
HUP9901790A2 HU9901790A HUP9901790A HUP9901790A2 HU P9901790 A2 HUP9901790 A2 HU P9901790A2 HU 9901790 A HU9901790 A HU 9901790A HU P9901790 A HUP9901790 A HU P9901790A HU P9901790 A2 HUP9901790 A2 HU P9901790A2
Authority
HU
Hungary
Prior art keywords
genetic material
transfer system
virosomes
cationic virosomes
cationic
Prior art date
Application number
HU9901790A
Other languages
English (en)
Inventor
Reinhard Glück
Peter Klein
Ernst Rudolf Wälti
Original Assignee
Nika Health Products Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nika Health Products Limited filed Critical Nika Health Products Limited
Publication of HUP9901790A2 publication Critical patent/HUP9901790A2/hu
Publication of HUP9901790A3 publication Critical patent/HUP9901790A3/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Manufacturing Of Micro-Capsules (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

A találmány tárgyát új virőszómák, azaz membránjűkban virálisglikőprőteineket tartalmazó, pőzitívan töltött lipőszóma-vezikűlákképezik genetikai anyag hatékőny célba jűttatására. A találmánytárgyát képezik tővábbá eljárásők a lipőszómák előállítására, tővábbáazők alkalmazásai. A találmány szerinti katiőnős virőszómák alkalmasakgéneknek célsejtekbe történő specifikűs és nem specifikűs, nem fertőzőcélba jűttatására, in vitrő és in vivő egyaránt. ŕ
HU9901790A 1996-05-08 1997-05-04 Cationic virosomes as transfer system for genetic material HUP9901790A3 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP96107282 1996-05-08

Publications (2)

Publication Number Publication Date
HUP9901790A2 true HUP9901790A2 (hu) 1999-08-30
HUP9901790A3 HUP9901790A3 (en) 2010-11-29

Family

ID=8222763

Family Applications (1)

Application Number Title Priority Date Filing Date
HU9901790A HUP9901790A3 (en) 1996-05-08 1997-05-04 Cationic virosomes as transfer system for genetic material

Country Status (28)

Country Link
US (1) US6210708B1 (hu)
EP (1) EP0902682A2 (hu)
JP (1) JP2000509404A (hu)
KR (1) KR100536983B1 (hu)
CN (1) CN1271992C (hu)
AR (1) AR007054A1 (hu)
AU (1) AU710170B2 (hu)
BG (1) BG102880A (hu)
BR (1) BR9709224A (hu)
CA (1) CA2253561A1 (hu)
CO (1) CO4600638A1 (hu)
CZ (1) CZ299809B6 (hu)
EA (1) EA003130B1 (hu)
GT (1) GT199700058A (hu)
HR (1) HRP970234B1 (hu)
HU (1) HUP9901790A3 (hu)
ID (1) ID17934A (hu)
NO (1) NO327726B1 (hu)
NZ (1) NZ332666A (hu)
OA (1) OA10916A (hu)
PA (1) PA8429201A1 (hu)
PE (1) PE65198A1 (hu)
PL (1) PL199201B1 (hu)
SK (1) SK152698A3 (hu)
SV (1) SV1997000032A (hu)
TN (1) TNSN97080A1 (hu)
WO (1) WO1997041834A1 (hu)
ZA (1) ZA973885B (hu)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030113347A1 (en) * 1991-05-08 2003-06-19 Schweiz. Serum- & Impfinstitut Bern Immunostimulating and immunopotentiating reconstituted influenza virosomes and vaccines containing them
EP1011735A1 (en) * 1997-09-08 2000-06-28 Promega Corporation METHOD OF $i(IN VIVO) TRANSFORMATION UTILIZING LIPID VEHICLES
SE513149C2 (sv) * 1997-12-05 2000-07-17 Katarina Edwards Läkemedelsdistributionssystem med tvåstegsmålsökning, till specifika celler eller vävnad och till dess cellkärna
TR200200930T2 (tr) * 1999-10-08 2002-08-21 Nika Health Products Limited Katyonik dosper virosomlar
BR0016472A (pt) * 1999-12-17 2002-08-20 Cápsula de ignição indutivamente ativável para sistemas de retenção de ocupantes de assento
EP1252897A4 (en) * 2000-01-21 2003-07-30 Hisamitsu Pharmaceutical Co MEDICINES FOR GENE THERAPY
JP2004536607A (ja) * 2001-07-23 2004-12-09 オニックス ファーマシューティカルズ，インコーポレイティド 標的化されたヒト癌細胞において選択的に複製するウイルス変異体
KR100411234B1 (ko) * 2001-08-14 2003-12-18 한국과학기술원 올리고뉴클레오티드 혼성화 미셀 및 그의 제조방법
WO2003038103A1 (en) * 2001-10-29 2003-05-08 Atso Raasmaja Method for gene transfection using synergistic combinations of cationic lipids and cationic polymers
US20040028687A1 (en) * 2002-01-15 2004-02-12 Waelti Ernst Rudolf Methods and compositions for the targeted delivery of therapeutic substances to specific cells and tissues
US20040176283A1 (en) * 2002-04-01 2004-09-09 Robinson John A. Methods and compositions for the design of synthetic vaccines
EP1562550A1 (en) * 2002-11-21 2005-08-17 Pevion Biotech Ltd. High-efficiency fusogenic vesicles, methods of producing them, and pharmaceutical compositions containing them
US20090208478A1 (en) * 2003-10-24 2009-08-20 Gencia Corporation Transducible polypeptides for modifying metabolism
US8507277B2 (en) 2003-10-24 2013-08-13 Gencia Corporation Nonviral vectors for delivering polynucleotides
US20090123468A1 (en) 2003-10-24 2009-05-14 Gencia Corporation Transducible polypeptides for modifying metabolism
US8062891B2 (en) 2003-10-24 2011-11-22 Gencia Corporation Nonviral vectors for delivering polynucleotides to plants
WO2005056752A2 (en) 2003-10-24 2005-06-23 Gencia Corporation Methods and compositions for delivering polynucleotides
US8133733B2 (en) 2003-10-24 2012-03-13 Gencia Corporation Nonviral vectors for delivering polynucleotides to target tissues
DE102004057303A1 (de) * 2004-11-26 2006-06-01 Merck Patent Gmbh Stabile Kristallmodifikationen von DOTAP Chlorid
US20070172520A1 (en) * 2005-11-18 2007-07-26 University Of South Florida Immunotargeting of Nonionic Surfactant Vesicles
CA2663034C (en) * 2006-09-15 2016-05-03 Ottawa Health Research Institute Oncolytic rhabdovirus
KR101242113B1 (ko) * 2010-10-22 2013-03-19 고마바이오텍(주) 유전자 전달용 양이온성 센다이 ｆ／ｈｎ 바이로좀 복합체
WO2013032643A2 (en) * 2011-08-31 2013-03-07 Dicerna Pharmaceuticals, Inc. Lipids capable of conformational change and their use in formulations to deliver therapeutic agents to cells
WO2013050048A2 (en) * 2011-10-07 2013-04-11 Skau Aps Identification and attenuation of the immunosuppressive domains in fusion proteins of enveloped rna viruses
CN109789215B (zh) 2016-09-27 2022-12-16 卡姆拉斯公司 含有生长激素抑制素受体激动剂的制剂
CN109055432B (zh) * 2018-08-16 2020-10-13 南京科佰生物科技有限公司 慢病毒感染试剂及其制备方法与应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4261975A (en) 1979-09-19 1981-04-14 Merck & Co., Inc. Viral liposome particle
US5264618A (en) * 1990-04-19 1993-11-23 Vical, Inc. Cationic lipids for intracellular delivery of biologically active molecules
PL296382A1 (en) * 1991-02-02 1993-11-02 Nika Health Products Ltd Li Li Artificial membrane beads containing functionally active peptides responsible for fusion as a drug administering system
DE69229703T2 (de) * 1991-05-08 2000-04-27 Schweiz Serum & Impfinst Wiederhergestellte Influenza-Virosomen mit immunostimulierenden und immunoverstärkenden Eigenschaften und diese enthaltende Impfstoffe
WO1993014744A1 (en) 1992-02-04 1993-08-05 Chiron Corporation Non-toxic lipid vaccine formulations
US5631237A (en) 1992-12-22 1997-05-20 Dzau; Victor J. Method for producing in vivo delivery of therapeutic agents via liposomes
US5578475A (en) * 1993-07-12 1996-11-26 Life Technologies, Inc. Composition and methods for transfecting eukaryotic cells
DE69528170T2 (de) * 1994-05-31 2003-05-22 Inex Pharmaceuticals Corp Intrazelluläre verabreichung therapeutischer sustanzenmittels virosomen
FR2726764B1 (fr) 1994-11-14 1997-01-31 Pasteur Merieux Serums Vacc Adjuvant pour composition vaccinale

Also Published As

Publication number Publication date
AU710170B2 (en) 1999-09-16
EP0902682A2 (en) 1999-03-24
CN1225007A (zh) 1999-08-04
AR007054A1 (es) 1999-10-13
HRP970234A2 (en) 1998-06-30
AU2776697A (en) 1997-11-26
BG102880A (en) 1999-05-31
OA10916A (en) 2003-02-21
CN1271992C (zh) 2006-08-30
HUP9901790A3 (en) 2010-11-29
EA003130B1 (ru) 2003-02-27
TNSN97080A1 (fr) 2005-03-15
PE65198A1 (es) 1998-10-16
NZ332666A (en) 2000-05-26
HRP970234B1 (en) 2002-04-30
NO985137D0 (no) 1998-11-04
CA2253561A1 (en) 1997-11-13
JP2000509404A (ja) 2000-07-25
NO985137L (no) 1999-01-04
WO1997041834A1 (en) 1997-11-13
US6210708B1 (en) 2001-04-03
CZ299809B6 (cs) 2008-12-03
KR100536983B1 (ko) 2006-06-29
SK152698A3 (en) 1999-05-07
ID17934A (id) 1998-02-12
PA8429201A1 (es) 2000-05-24
EA199800992A1 (ru) 1999-06-24
BR9709224A (pt) 1999-08-10
KR20000010780A (ko) 2000-02-25
PL329853A1 (en) 1999-04-12
SV1997000032A (es) 1998-03-27
GT199700058A (es) 1998-10-29
NO327726B1 (no) 2009-09-14
PL199201B1 (pl) 2008-08-29
CZ361498A3 (cs) 1999-03-17
CO4600638A1 (es) 1998-05-08
ZA973885B (en) 1998-11-06

Similar Documents

Publication Publication Date Title
HUP9901790A2 (hu) Kationos viroszómák mint genetikai anyag bevitelére alkalmas rendszerek
DE69906977D1 (de) In liposomen verkapselte nukleinsäurekomplexe
AU2284697A (en) Fusogenic liposomes
WO1999064565A3 (en) Regulation of hematopoietic stem cell differentiation by the use of human mesenchymal stem cells
ZA942719B (en) Expression of heterologous genes
DK0883602T3 (da) Lipidforbindelser
ATE279912T1 (de) Verfahren zur zelltransfektion mit liposomal- verkapselten nukleinsäuren
RU95108217A (ru) Дефектный рекомбинантный аденовирус, линия клеток, фармацевтическая композиция
AU4266597A (en) Use of a non-mammalian dna virus to express an exogenous gene in a mammalian cell
ATE437951T1 (de) Intrazelluläre herstellung von verkürztem hepatitis c-polypeptid e2
DE60023600D1 (de) Replizierende retrovirale Konstrukte, ihre Herstellung und Verwendungen für den Gentransfer
PL336983A1 (en) Compounds, their production and application as carriers of nucleic acids in cells
AU1265097A (en) Nucleic acid constructs for the cell cycle-regulated expression of genes, cells containing such constructs and their use for preparing drugs
PT835137E (pt) Celulas encapsuladas produtoras de particulas virais
WO1999058656A3 (en) Sustained dna delivery from structural matrices
AU2149099A (en) Pseudo-type retroviral vectors with modifiable surface capsid proteins
DK0843731T3 (da) Adenovirusvektorer til genterapi
EP1020529A3 (en) Gene delivery vectors provided with a tissue tropism for smooth muscle cells, and/or endothelial cells
EP0909811A3 (en) Bioreactor for culturing animal and/or human cells, particularly hepatocytes
DE69716581T2 (de) Retroviraler vektor und dessen verwendung in gentherapie
BR9400600A (pt) Processos para produção de uma protéina recombinante e/ou de glicosilfosfatidilinositol (GPI) em células de microorganismos eucariontes e para a obtenção de leveduras de S. cerevisae; célula de levedura sequência de nucleotídios; meio de cultura; medicamento ou vacina; e produto dos ditos processos
CA2441535A1 (en) Methods for delivering nucleic acid molecules into cells and assessment thereof
ATE359372T1 (de) Vektoren zur inhibierung von viralem und tumorwachstum
BR9814255A (pt) Partìculas de transfecção
ATE403735T1 (de) Episomaler vektor und dessen verwendung

Legal Events

Date Code Title Description
FD9A Lapse of provisional protection due to non-payment of fees